50 jili super ace
Idaho State men's head basketball coach Ryan Looney said before this season began, his goal for the Bengals’ “money games” against Power Conference schools is to come back a better team. If the second half of Wednesday night’s game against the Big Ten’s UCLA is any indication, it was mission accomplished. No, the Bengals didn’t win, nor did it ever really feel like they were going to contend for that matter. But they put together probably their best offensive half of the season, considering the opposition, while losing 84-70. It was the most points UCLA has given up at home this year by a wide margin – the previous high was 50 to Rider. And the Bengals, who had been in an early-season shooting slump, rose up to shoot 55% from the field in the second half, after hitting just 32% and trailing 41-27 at halftime. Unfortunately for ISU, the Bruins, now 4-1, were pretty hot from the field themselves. They shot 57% for the game, including a red hot 64% from 3-point range (9-of-14). Tyler Bilodeau, a 6-foot-9-inch transfer forward who scored only three points for Oregon State against the Bengals last season, lit it up from outside Wednesday. He was 4-for-4 from distance, and wound up with 20 points. Meanwhile, Sebastian Mack, a powerful 6-3 guard, made a living at the free throw line for the Bruins, hitting 15-of-16 foul shots on his way to 21 points. His backcourt mate, Eric Dailey, Jr., added 16 points on 7-of-9 shooting. So UCLA had plenty of firepower to put the game away. What was encouraging for the Bengals, however, is how well they performed offensively against a team that was holding opponents to 51.8 points a game, and forcing 19 turnovers a contest. ISU forward Isaiah Griffin was the Bengal offense in the first half, scoring the team’s first 12 points. He wound up with 16 total on 5-of-8 shooting, including 3-of-6 from 3-point range. Then in the second half, guard Dylan Darling, struggling from beyond-the-arc, starting take the ball inside and wound up with 13 points on 5-of-10 shooting. Guard AJ Burgin came off the bench to hit three 3s on the way to 11 points, and redshirt freshman Jaedyn Brown had his best game as a Bengal, hitting a pair of treys and finishing with 10 points. As a team, the Bengals only turned the ball over 12 times versus the Bruins’ full-court, man-to-man pressure. ISU was outrebounded for the first time this season, 25-23. But it still had more offensive rebounds, 10-8, than UCLA, which was playing before a sparse crowd of 4,029 fans in historic Pauley Pavilion. The Bruins, who used to be the “gold standard” in college basketball decades ago, haven’t played before a home crowed larger than 5,108 fans so far in their four home games this season. The Bengals fall to 2-4 on the season, but their tour of “money games” is now over. They return home to take on Embry-Riddle Aeronautical University Monday at 7 p.m. at Reed Gym.
Delhi minister Saurabh Bharadwaj alleges attacker wanted to ‘burn Kejriwal alive’
Hitster has now arrived here in the Philippines! In a country where music holds a very dear place in its culture, get ready to sing, dance, and showcase your music knowledge with Hitster! From classic hits such as “I wanna Dance with Somebody” by Whitney Houston, something a bit more modern like Billie Eilish’s “Bad Guy” or even something that stay’s true to our culture like BINI’s Pantropiko, Hitster has it all. For group of friends or families that are looking for a perfect party game for this upcoming holiday, Hitster is the perfect way to get the party started! #HitsterPhilippineEdition #musicpartygame #RichwellClubPH Now available in all leading toy stores nationwide!Best TV of 2024: A modestly better lineup than usual, but why didn’t it feel that way?Technology stocks helped pull stocks lower on Wall Street Wednesday, handing the market its first loss in more than a week. The S&P 500 fell 0.4%, even though more stocks in the index notched gains than ended lower. The loss snapped a seven-day winning streak for the benchmark index. The Dow Jones Industrial Average fell 0.3%, its first loss after five gains. The Dow and S&P 500 remain near the all-time highs they set on Tuesday. The Nasdaq composite, which is heavily weighted with technology stocks, fell 0.6%. Losses for tech heavyweights like Nvidia, Microsoft and Broadcom were the drag on the market. Semiconductor giant Nvidia fell 1.2%. Its huge value gives it outsized influence on market indexes. Microsoft fell 1.2% and Broadcom finished 3.1% lower. Several personal computer makers also helped pull the market lower following their latest earnings reports. HP sank 11.4% after giving investors a weaker-than-expected earnings forecast for its current quarter. Dell slid 12.2% after its latest quarterly revenue fell short of Wall Street forecasts. Gains for financial and health care companies helped temper the market's losses. Berkshire Hathaway rose 0.9% and Merck & Co. added 1.5%. All told, the S&P 500 fell 22.89 points to 5,998.74, while the Dow dropped 138.25 points to 44,722.06. The Nasdaq fell 115.10 points to 19,060.48. Traders also had their eye on new reports on the economy and inflation Wednesday. The U.S. economy expanded at a healthy 2.8% annual pace from July through September, according to the Commerce Department, leaving its original estimate of third-quarter growth unchanged. The growth was driven by strong consumer spending and a surge in exports. The update followed a report on Tuesday from the Conference Board that said confidence among U.S. consumers improved in November, but not by as much as economists expected. Consumers have been driving economic growth, but the latest round of earnings reports from retailers shows a mixed and more cautious picture. Department store operator Nordstrom fell 8.1% after warning investors about a trend toward weakening sales that started in late October. Clothing retailer Urban Outfitters jumped 18.3% after beating analysts’ third-quarter financial forecasts. Weeks earlier, retail giant Target gave investors a discouraging forecast for the holiday season, while Walmart provided a more encouraging forecast. Consumers, though resilient, are still facing pressure from inflation. The latest update from the U.S. government shows that inflation accelerated last month. The personal consumption expenditures index, or PCE, rose to 2.3% in October from 2.1% in September. Overall, the rate of inflation has been falling broadly since it peaked more than two years ago. The PCE, which is the Federal Reserve's preferred measure of inflation, was just below 7.3% in June of 2022. Another measure of inflation, the consumer price index, peaked at 9.1% at the same time. The latest inflation data, though, is a sign that the rate of inflation seems to be stalling as it falls to within range of the Fed's target of 2%. The central bank started raising its benchmark interest rate from near-zero in early 2022 to a two-decade high by the middle of 2023 and held it there in order to tame inflation. The Fed started cutting its benchmark interest rate in September, followed by a second cut in November. Wall Street expects a similar quarter-point cut at the central bank's upcoming meeting in December. “Today’s data shouldn’t change views of the likely path for disinflation, however bumpy," said David Alcaly, lead macroeconomic strategist at Lazard Asset Management. "But a lot of observers, probably including some at the Fed, are looking for reasons to get more hawkish on the outlook given the potential for inflationary policy change like new tariffs.” President-elect Donald Trump has said he plans to impose sweeping new tariffs on Mexico, Canada and China when he takes office in January. That could shock the economy by raising prices on a wide range of goods and accelerating the rate of inflation. Such a shift could prompt the Fed to rethink future cuts to interest rates. Treasury yields slipped in the bond market. The yield on the 10-year Treasury fell to 4.25% from 4.30% late Tuesday. The yield on the two-year Treasury, which more closely follows expected actions by the Fed, fell to 4.22% from 4.25% late Tuesday. U.S. markets will be closed Thursday for Thanksgiving, and will reopen for a half day on Friday.
NoneNone
49ers' Deebo Samuel Seemingly Takes Shot at Team Amid Recent SlumpGuest column: Delaware County taxes are set to soar: What now, Delco?
Ernst Backs Hegseth after Meeting: ‘As I Support Pete Through This Process,’ Anonymous Smears Will Not Fly
"Perfect" AI Girlfriend Could Worsen Loneliness Epidemic Among Men: Ex-Google CEO
The midseason four-game winning streak that lifted the Arizona Cardinals into the playoff picture seemed as though it happened fast. Their subsequent free fall has been even more jarring. The Cardinals could have moved into a tie for first place in the NFC West with a home win over the Seattle Seahawks on Sunday. Instead, they were thoroughly outplayed in a 30-18 loss and are now tied for last in the tightly packed division. Arizona has lost three straight and will face an uphill battle to return to the playoffs for the first time since 2021. The Seahawks (8-5) are in first place, followed by the Rams (7-6), Cardinals (6-7) and 49ers (6-7). Even more daunting for their playoff hopes, the Cardinals lost both of their games against the Seahawks this season, meaning a tiebreaker would go to Seattle. Four games remain. “I just told them we put ourselves in a little bit of a hole now, but all you can do is attack tomorrow, learn tomorrow and have a good week of practice,” second-year coach Jonathan Gannon said. There are plenty of reasons the Cardinals lost to the Seahawks, including Kyler Murray's two interceptions, a handful of holding penalties, a porous run defense and a brutal missed field goal. It all adds up to the fact Arizona is playing its worst football of the season at a time when it needed its best. “I’m sure we’ll stick to our process, but we have to tweak some things,” Gannon said. "I have to tweak some things.” It's probably faint praise, but the Cardinals did make the game interesting in the second half while trying to fight back from a 27-10 deficit. Murray's shovel pass to James Conner for a 2-yard touchdown and subsequent 2-point conversion cut the margin to 27-18. The Cardinals had a chance to make it a one-score contest early in the fourth quarter, but Chad Ryland's 40-yard field goal attempt bounced off the left upright. “I thought we spotted them a lot of points there, but then we battled back,” Gannon said. “I appreciate their effort. That was good. We battled back there, had a couple chances to even cut the lead a little more, but ultimately didn’t get it done." Murray's in a bit of a mini-slump after throwing two interceptions in back-to-back games for the first time in his career. He also didn't do much in the run game against the Seahawks, with 16 yards on three carries. The quarterback's decision-making was nearly flawless for much of the season and the Cardinals need that good judgment to return. “I’m not looking at it like I have to try to be Superman,” Murray said. “I don’t think that’s the answer. I just need to play within the offense like we’ve done for the majority of the season. Today, I didn’t. Like I said, throwing two picks puts yourself behind the eight ball.” Said Gannon: “I thought he stuck in there and made some big time throws, though, but he has to protect the ball a little bit better. That’s not just him, that’s all 11. So there’ll be a lot of corrections off those plays." The defense didn't have its best day, but it's not Budda Baker's fault. The two-time All-Pro safety is having another phenomenal season and was all over the field against the Seahawks, finishing with 18 tackles. Baker's energy is relentless and he's the unquestioned leader of a group that has been better than expected this season, even with Sunday's mediocre performance. Left tackle Paris Johnson Jr. had a tough day, getting flagged for holding three times, though one of those penalties was declined by the Seahawks. The second-year player moved from right tackle to the left side during the offseason and the transition has gone well, but Sunday was a step backward. The Cardinals remain fairly healthy. DL Roy Lopez (ankle) and P Blake Gillikin (ankle) left Sunday's game, but neither injury is expected to be long term. 9 — It looks as if the Cardinals will go a ninth straight season without winning the NFC West. The last time they won the division was 2015 with coach Bruce Arians and a core offense of quarterback Carson Palmer, running back David Johnson and receiver Larry Fitzgerald. The Cardinals are in must-win territory now for any chance at the playoffs. They'll host the New England Patriots on Sunday. AP NFL: https://apnews.com/hub/NFLSC notice to CBI on Indrani's plea for nod to visit UK, SpainMongoDB Stock Surges On Big Earnings Beat For Database Software Player
Cassie Randolph did not find her happily ever after on The Bachelor , but she found The One in Brighton Reinhardt . Randolph competed on season 23 of the ABC series. She won Colton Underwood ’s season despite leaving early, but the pair parted ways in May 2020. (Underwood came out publicly as gay in April 2021.) Shortly after their split, Randolph began dating Reinhardt. The couple went public with their romance in July 2021 after nearly one year together. That same year, Randolph starred in Reinhardt’s “Dreaming” music video, and they’ve since become regulars on each other’s social media pages. You have successfully subscribed. By signing up, I agree to the Terms and Privacy Policy and to receive emails from Us Weekly Check our latest news in Google News Check our latest news in Apple News Randolph and Reinhardt got engaged in November 2024 after four years of dating. Scroll down to revisit Randolph and Reinhardt’s romance: Credit: Courtesy Brighton Reinhardt/Instagram Cassie Randolph and Fiance Brighton Reinhardt: A Timeline of Their Relationship Cassie Randolph did not find her happily ever after on The Bachelor , but she found The One in Brighton Reinhardt .Randolph competed on season 23 of the ABC series. She won Colton Underwood ’s season despite leaving early, but the pair parted ways in May 2020. (Underwood came out publicly as gay in April 2021.)Shortly after their split, Randolph began dating Reinhardt. The couple went public with their romance in July 2021 after nearly one year together. That same year, Randolph starred in Reinhardt’s “Dreaming” music video, and they’ve since become regulars on each other’s social media pages.Randolph and Reinhardt got engaged in November 2024 after four years of dating.Scroll down to revisit Randolph and Reinhardt’s romance: Credit: Sara De Boer/startraksphoto.com; Courtesy Brighton Reinhardt/Instagram; Chelsea Lauren/Shutterstock August 2020 The duo sparked dating rumors three months after her split from Underwood. Fans noticed them spending time together with her family in Huntington Beach, California, and “liking” each other’s Instagram posts. However, Reinhardt shut down the speculation in August 2020. “Cassie and I are just friends and have been for over four or so years,” he exclusively told Us at the time. “My brothers and I are all close with Cassie and her whole family.” Credit: Shutterstock; Courtesy Brighton Reinhardt/Instagram; Shutterstock January 2021 The musician seemingly shaded Underwood in his song “Creep,” two months after Randolph dropped her restraining order against her ex. (Randolph accused Underwood of installing a tracker on her car. Randolph rescinded the order after coming to an agreement with Underwood.) The lyrics, in part, read, “You can’t stop thinking about my baby / What once was yours in the world is changing / God, I hope you get your thinking right / GPS on the underside / Told her everything will be just fine / Damn, I can’t believe these guys.” Credit: John Nacion/Startraks; Courtesy Brighton Reinhardt/Instagram; Shutterstock May 2021 A source told Us that the speech pathologist’s relationship with Reinhardt “progressed naturally” after her split from the former Bachelor. “He’s been a good friend of hers for over five years,” the insider noted. “He obviously knows what she went through with Colton and just supported her along the way.” Reinhardt “gets along well with her family,” the source said, adding that the twosome were “still enjoying spending time with one another and just seeing where things go.” Credit: Courtesy Brighton Reinhardt/Instagram July 2021 Randolph and Reinhardt made their relationship Instagram official in July 2021. “Insert cheesy caption here*,” he captioned the beach pics. Credit: CraSH/imageSPACE/Shutterstock; Courtesy Brighton Reinhardt/Instagram August 2021 Randolph appeared in the music video for her boyfriend’s song “Dreaming” in August 2021. “This song is obviously very special to me,” she explained via Instagram at the time. “About 5 months ago when it was just a demo, I began using it as my YouTube intro song, and shortly after @briighton trusted me to attempt to sing some background vocals on it! In a funny way I feel like this song is one of my kittens that I’ve been watching grow up ... Anywho, we’ve been SO impatiently waiting to share this with you all.” Credit: Cassie Randolph/Instagram September 2021 One month after Randolph starred in the "Dreaming" video, a source told Us that the couple were happier than ever. "She's in a very normal dating relationship with Brighton," the insider said. "They're very much in love. They are really happy and just enjoying life." The source noted that they hadn't moved in together yet, but are still spending much of their free time with each other. "In their downtime, they're always at the beach — surfing, swimming, laying out," the insider explained. "She's very active and has been doing lots of yoga and meditation. They also like creating videos together and taking photos, capturing special moments of them together." Credit: Oscar Chan - Momentum Photography November 2021 The reality TV alum and the musician enjoyed a romantic getaway together at Garza Blanca Resort & Spa Cancun in Cancun, Mexico. “They seemed to be very much in love and were seen being affectionate and cuddling on the beach cabanas and poolside lounge chairs,” an eyewitness recalled to Us Weekly at the time. "They also enjoyed a romantic candlelit private dinner set up by the resort in their suite and took long walks hand in hand on the beach.” Credit: Courtesy of Brighton Reinhardt/Instagram March 2022 "He's a great person," Randolph gushed about her man during an episode of the "Off the Vine" podcast in March 2022. "It's very, like, natural. So easy. Which I never understood until this [relationship]. ... I'm never questioning him or us. It's more just we get annoyed at little things." While reflecting on their next steps, Randolph noted, "We've definitely talked about the future. There's no, like, plans on the horizon that I am aware of." Credit: Courtesy of Brighton Reinhardt/Instagram April 2022 Reinhardt celebrated Randolph’s birthday by taking her to Stagecoach Music Festival in Indio, California. Credit: Courtesy of Cassie Randolph/Instagram August 2023 The pair celebrated three years together by sharing two disposable camera photos via Instagram. Credit: Courtesy of Brighton Reinhardt/Instagram July 2024 “First time at Yosemite! ✅ Hiked enough for the rest of the year 😅,” Reinhardt captioned a series of photos from the couple’s national park trip. Credit: Paul Archuleta/Getty Images November 2024 Reinhardt proposed on November 25 at the Crystal Cove Cottages in Newport Beach, California. “Forever with my best friend,” the musician captioned an IG Story photo after news of their engagement broke. “When Brighton dropped to a knee and asked ‘Will you marry me?,’ as he opened the box, my reaction was immediately, ‘Oh, my gosh, yes!,’” Randolph told People of the special moment. In order to view the gallery, please allow Manage Cookies For access to all our exclusive celebrity videos and interviews – Subscribe on YouTube!‘I wouldn’t be where I am without bumiputera rights’: Malaysia’s young Malays talk race and privilege
REYKJAVIK, Iceland (AP) – Icelanders are electing a new parliament Saturday after disagreements over immigration, energy policy and the economy forced Prime Minister Bjarni Benediktsson to pull the plug on his coalition government and call an early election. This is Iceland’s sixth general election since the 2008 financial crisis devastated the economy of the North Atlantic island nation and ushered in a new era of political instability. Opinion polls suggest the country may be in for another upheaval, with support for the three governing parties plunging. Benediktsson, who was named prime minister in April following the resignation of his predecessor, struggled to hold together the unlikely coalition of his conservative Independence Party with the centrist Progressive Party and the Left-Green Movement. Iceland, a nation of about 400,000 people, is proud of its democratic traditions, describing itself as arguably the world’s oldest parliamentary democracy. The island’s parliament, the Althingi, was founded in 930 by the Norsemen who settled the country. Fierce weather in the sub-Arctic nation threatened to hamper some voters getting to polling stations on Saturday, with heavy snow blocking roads in many areas. The weather could also delay the delivery of ballot boxes to counting centers after polls close at 10 p.m. (2200GMT). Here’s what to look for in the contest. Voters will choose 63 members of the Althingi in an election that will allocate seats both by regional constituencies and proportional representation. Parties need at least 5% of the vote to win seats in parliament. Eight parties were represented in the outgoing parliament, and 10 parties are contesting this election. Turnout is traditionally high by international standards, with 80% of registered voters casting ballots in the 2021 parliamentary election. A windswept island near the Arctic Circle, Iceland normally holds elections during the warmer months of the year. But on Oct. 13 Benediktsson decided his coalition couldn’t last any longer, and he asked President Halla Tómasdóttir to dissolve the Althingi. vhttps://twitter.com/BreitbartLondon/status/1797368452119761236 “The weakness of this society is that we have no very strong party and we have no very strong leader of any party,” said Vilhjálmur Bjarnason a former member of parliament. “We have no charming person with a vision ... That is very difficult for us.” The splintering of Iceland’s political landscape came after the 2008 financial crisis, which prompted years of economic upheaval after the country’s debt-swollen banks collapsed. The crisis led to anger and distrust of the parties that had traditionally traded power back and forth, and prompted the creation of new parties ranging from the environment focused Left-Green Alliance to the Pirate Party, which advocates direct democracy and individual freedoms. “This is one of the consequences of the economic crash,” said Eva H. Önnudóttir, a professor of political science at the University of Iceland. “It’s just the changed landscape. Parties, especially the old parties, have maybe kind of been hoping that we would go back to how things were before, but that’s not going to happen.” Like many Western countries, Iceland has been buffeted by the rising cost of living and immigration pressures. Inflation peaked at an annual rate of 10.2% in February 2023, fueled by the fallout from the COVID-19 pandemic and Russia’s invasion of Ukraine. While inflation slowed to 5.1% in October, that is still high compared with neighboring countries. The U.S. inflation rate stood at 2.6% last month, while the European Union ́s rate was 2.3%. Iceland is also struggling to accommodate a rising number of asylum-seekers, creating tensions within the small, traditionally homogenous country. The number of immigrants seeking protection in Iceland jumped to more than 4,000 in each of the past three years, compared with a previous average of less than 1,000. Repeated eruptions of a volcano in the southwestern part of the country have displaced thousands of people and strained public finances. One year after the first eruption forced the evacuation of the town of Grindavik, many residents still don’t have secure housing, leading to complaints that the government has been slow to respond. But it also added to a shortage of affordable housing exacerbated by Iceland ́s tourism boom. Young people are struggling to get a foot on the housing ladder at a time when short-term vacation rentals have reduced the housing stock available for locals, Önnudóttir said. “The housing issue is becoming a big issue in Iceland,” she said.Terry Prone: Gemma Hussey was a true pioneer of women's rights in Ireland
Luke Williams feels Swansea ‘lost grip’ on game despite sealing victory at Derby
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company’s FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. “We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation,” said Bob Valamehr, President of Research and Development of Fate Therapeutics. “We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization.” FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company’s FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study’s conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled “ Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ”, the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled “ Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ”, the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics’ iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company’s iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the timing and availability of data from the Company’s clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 christina.tartaglia@precisionaq.comBill on technology transfer commission scales second reading
Medical marijuana operators ready to light upPICTORIAL: Ex-VP Atiku Hosts Peter Obi In AdamawaOne of my top shows of 2024 actually premiered in 2021. That’s because it took a couple of years for the Australian series “The Newsreader” to make its way Stateside. Alas, it was only legal to stream in the U.S. for a handful of weeks in September and then — pffft! — it was gone before most people had even heard of it. Well, I have great news. The show will be available once again, this time via Sundance Now (accessible through the AMC+ streaming platform), which has licensed the first season. Premiering Dec. 19, it stars Anna Torv (“Fringe”) and Sam Reid (“Interview with the Vampire”) as TV reporters in Melbourne, circa 1986. At the outset, Reid’s character exudes big loser energy, which is such an amusing contrast to his work as Lestat. The show is unexpectedly funny and terrifically Machiavellian in its portrayal of small-time office politics, and I’m thrilled audiences in the U.S. will get another shot at watching it. Overall, 2024 offered a modestly better lineup than usual, but I’m not sure it felt that way. Too often the good stuff got drowned out by Hollywood’s pointless and endless pursuit of rebooting intellectual property (no thank you, Apple’s “Presumed Innocent” ) and tendency to stretch a perfectly fine two-hour movie premise into a saggy multi-part series (“Presumed Innocent” again!). There were plenty of shows I liked that didn’t make this year’s list, including ABC’s “Abbott Elementary” and CBS’ “Ghosts” (it’s heartening to see the network sitcom format still thriving in the streaming era), as well as Netflix’s “A Man on the Inside” (Ted Danson’s charisma selling an unlikely premise) and Hulu’s “Interior Chinatown” (a high-concept parody of racial stereotypes and cop show tropes, even if it couldn’t sustain the idea over 10 episodes). Maybe it just felt like we were having more fun this year, with Netflix’s “The Perfect Couple” (Nicole Kidman leading a traditional manor house mystery reinterpreted with an American sensibility) and Hulu’s “Rivals” (the horniest show of 2024, delivered with a wink in the English countryside). I liked what I saw of Showtime’s espionage thriller “The Agency” (although the bulk of episodes were unavailable as of this writing). The deluge of remakes tends to make me cringe, but this year also saw a redo of Patricia Highsmith’s “The Talented Mr. Ripley” on Netflix that was far classier than most of what’s available on the streamer. Starring Andrew Scott, I found it cool to the touch, but the imagery stayed with me. Shot in black and white, it has an indelible visual language courtesy of director of photography Robert Elswit, whether capturing a crisp white business card against the worn grain wood of a bar top, or winding stairways that alternately suggest a yawning void or a trap. As always, if you missed any of these shows when they originally premiered — the aforementioned titles or the Top 10 listed below — they are all available to stream. Top 10 streaming and TV shows of 2024, in alphabetical order: “Couples Therapy” (Showtime) The least cynical reality show on television remains as absorbing as ever in Season 4, thanks to the probing questions and insights from the show’s resident therapist, Dr. Orna Guralnik. Everything is so charged. And yet the show has a soothing effect, predicated on the idea that human behavior (and misery) isn’t mysterious or unchangeable. There’s something so optimistic in that outlook. Whether or not you relate to the people featured on “Couples Therapy” — or even like them as individuals — doesn’t matter as much as Guralnik’s reassuring presence. “Diarra From Detroit” (BET+) Created by and starring Diarra Kilpatrick, the eight-episode series defies categorization in all the right ways. Part missing-person mystery, part comedy about a school teacher coming to grips with her impending divorce, and part drama about long-buried secrets, it has tremendous style right from the start — sardonic, knowing and self-deprecating. The answers to the central mystery may not pack a satisfying punch by the end, but the road there is as entertaining and absorbing as they come. We need more shows like this. “English Teacher” (FX) A comedy created by and starring Brian Jordan Alvarez (of the antic YouTube series “The Gay and Wondrous Life of Caleb Gallo”), the show has a sensibility all its own, despite a handful of misinformed people on social media calling it a ripoff of “Abbott Elementary.” There’s room enough in the TV landscape for more than one sitcom with a school setting and “English Teacher” has a wonderfully gimlet-eyed point of view of modern high school life. I’m amused that so much of its musical score is Gen-X coded, because that neither applies to Alvarez (a millennial) nor the fictional students he teaches. So why does the show feature everything from Laura Branigan’s “Gloria” to Exposé’s “Point of No Return”? The ’80s were awash in teen stories and maybe the show is using music from that era to invoke all those tropes in order to better subvert them. It’s a compelling idea! It’s streaming on Hulu and worth checking out if you haven’t already. “Fifteen-Love” (Sundance Now) A one-time tennis phenom accuses her former coach of coercing her into a sexual relationship in this British thriller. The intimacy between a coach and athlete often goes unexplored, in real-life or fictional contexts and that’s what the show interrogates: When does it go over the line? It’s smart, endlessly watchable and the kind of series that would likely find a larger audience were it available on a more popular streamer. “Hacks” (Max) There’s real tenderness in this show. Real cruelty, too. It’s a potent combination and the show’s third and strongest season won it an Emmy for best comedy. Jean Smart’s aging comic still looking for industry validation and Hannah Einbinder’s needy Gen-Z writer are trapped in an endless cycle of building trust that inevitably gives way to betrayal. Hollywood in a nutshell! “Hacks” is doing variations on this theme every season, but doing it in interesting ways. Nobody self-sabotages their way to success like these two. “Interview with the Vampire” (AMC) I was skeptical about the show when it premiered in 2022 . Vampire stories don’t interest me. And the 1994 movie adaptation starring Tom Cruise and Brad Pitt wasn’t a persuasive argument to the contrary. But great television is great television and nothing at the moment is better than this show. It was ignored by Emmy voters in its initial outing but let’s hope Season 2 gets the recognition it deserves. Under showrunner Rolin Jones, the adaptation of Anne Rice’s novels is richly written, thrillingly inhabited by its cast and so effortlessly funny with a framing device — the interview of the title — that is thick with intrigue and sly comedy. I wouldn’t categorize the series as horror. It’s not scary. But it is tonally self-assured and richly made, rarely focused on the hunt for dinner but on something far more interesting: The melodrama of vampire existence, with its combination of boredom and lust and tragedy and zingers. Already renewed for Season 3, it has an incredible cast (a thrilling late-career boost for Eric Bogosian) and is well worth catching up with if you haven’t already. “Nobody Wants This” (Netflix) It’s been too long since the pleasures of banter fueled a romantic comedy in the spirit of “When Harry Met Sally.” But it’s all over the place in “Nobody Wants This,” one of the best shows on Netflix in recent memory. Renewed for a second season, it stars Kristen Bell as a humorously caustic podcaster and Adam Brody as the cute and emotionally intelligent rabbi she falls for. On the downside, the show has some terrible notions about Jewish women that play into controlling and emasculating stereotypes. You hate to see it in such an otherwise sparkling comedy, because overall Bell and Brody have an easy touch that gives the comedy real buoyancy. “Nolly” (PBS Masterpiece) I suspect few people saw this three-part series on PBS Masterpiece, but it features a terrific performance by Helena Bonham Carter playing the real-life, longtime British soap star Noele “Nolly” Gordon, who was unceremoniously sacked in 1981. She’s the kind of larger-than-life showbiz figure who is a bit ridiculous, a bit imperious, but also so much fun. The final stretch of her career is brought to life by Carter and this homage — to both the soap she starred in and the way she carried it on her back — is from Russell T. Davies (best known for the “Doctor Who” revival). For U.S. viewers unfamiliar with the show or Gordon, Carter’s performance has the benefit of not competing with a memory as it reanimates a slice of British pop culture history from the analog era. “Shōgun” (FX) The year is 1600 and a stubborn British seaman piloting a Dutch ship washes ashore in Japan. That’s our entry point to this gorgeously shot story of power games and political maneuvering among feudal enemies. Adapted from James Clavell’s 1975 novel by the married team of Rachel Kondo and Justin Marks, it is filled with Emmy-winning performances (for Anna Sawai and Hiroyuki Sanada; the series itself also won best drama) and unlike something like HBO’s far clunkier “House of the Dragon,” which tackles similar themes, this feels like the rare show created by, and for, adults. “Slow Horses” (Apple TV+) The misfits and losers of Britain’s MI5 counterintelligence agency — collectively known as the slow horses, a sneering nickname that speaks to their perceived uselessness — remain as restless as ever in this adaptation of Mick Herron’s Slough House spy novels. As a series, “Slow Horses” doesn’t offer tightly plotted clockwork spy stories; think too deeply about any of the details and the whole thing threatens to fall apart. But on a scene-by-scene basis, the writing is a winning combination of wry and tension-filled, and the cumulative effect is wonderfully entertaining. Spies have to deal with petty office politics like everyone else! It’s also one of the few shows that has avoided the dreaded one- or two-year delay between seasons, which has become standard on streaming. Instead, it provides the kind of reliability — of its characters but also its storytelling intent — that has become increasingly rare. Nina Metz is a Tribune critic.
Ireland keeper hits the target as he takes on a darts challenge. Caoimhín Kelleher made his darting debut on the Sky Sports Youtube channel Caoimhín Kelleher has established himself as one of the stand-out performers in the Premier League this season and now he has confirmed he has a flair for another sport. Ireland’s No.1 Kelleher has turned in a series of impressive performances for Liverpool after stepping in for the injured Alisson Becker, with his penalty save from Kylian Mbappe last Wednesday paving the way for a 2-0 win for Arne Slot’s team. Now Kelleher has stepped out of his comfort zone between the sticks and tried his hand at darts as he took on Sky Sports reporter Kyle Walker. Sky are preparing to broadcast the 2025 World Darts Championship that gets underway in the middle of December and they gave Kelleher a chance to show if he could compete with Luke Humphries, Luke Littler and the rest of the game’s star names. While Kelleher will not be swapping goalkeeper gloves for ‘the arrows’ any time soon, he showed his talents by firing in a treble 20 on his first visit to the board and backed that up with a treble 19 on his third visit. He then won the leg with a less than conventional double double finish, as he inadvertently hit double six when he was aiming at double ten and he sealed his win with a double four on his first attempt. Kelleher rated his darts skills as a seven out of ten before he displayed his skills, but he admitted he needed a ‘bit more practice’ to get his darts game up to standard. You can check out how the Cork stopper got on below: We need your consent to load this Social Media content. We use a number of different Social Media outlets to manage extra content that can set cookies on your device and collect data about your activity.